SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (442)12/6/1999 10:32:00 PM
From: Vector1  Read Replies (2) of 666
 
This could explain the big drop in IDPH today. In patients who failed Rit the Zev complete response was zero. Thats right zero. I guess thats why they initially only reported the the overall response. Has anyone seen the complete response numbers in the Rit naive group.

From Prudential today:

---------------------
08:32am EST 6-Dec-99 Prudential Vector Healthcare (Toth, Robert J. 415-743-47
IDPH: ASH MEETING DOMINATED BY RITUXAN AND ZEVALIN STUDIES - 2 OF 2


IDEC presented interim Phase III data on Zevalin, its radiolabeled antibody
that is also being developed for low-grade NHL. In 29 evaluable patients
who had an inadequate response to Rituxan therapy, 46% achieved an overall
response to Zevalin. This result appears promising given the difficulty of
the patient population. However, none of these patients experienced a
complete response, which is one of the primary goals of oncologists who
treat low-grade NHL. The durability of the responses in this study were not
reported but should be a key factor in determining Zevalin's benefit
compared to Coulter's Bexxar. The Rituxan-failed patient population is in
our view the primary market for the new radio-immunotherapies, and we have
estimated its size today at around $225-250 million given the current
Rituxan sales trends. It is important to note that Grade 4 neutropenia was
reported for 28% of Zevalin-treated patients, and a company official told
us that at least several patients required rescue with white blood cell
growth factors. We believe that the magnitude of growth factor support may
become a differentiating factor between Bexxar and Zevalin and a
contributing component of the overall cost of treatment with the new
radiolabeled antibodies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News